Takeda Pharmaceuticals: Over half of psoriasis patients treated with Zasocitinib have completely or almost completely cleared skin lesions at 16 weeks.

Takeda Pharmaceutical has learned that the company has released the latest data from two key Phase 3 studies of the investigational drug Zasocitinib. Zasocitinib is a next-generation highly selective oral TYK2 inhibitor used to treat moderate to severe plaque psoriasis in adult patients.